4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $69.00

Goldman downgraded GE HealthCare from Buy to Neutral and set a new price target of $65.00

UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $77.00

Barclays initiated coverage of GE HealthCare with a rating of Equal Weight and set a new price target of $86.00

Citigroup downgraded GE HealthCare from Buy to Neutral and set a new price target of $83.00

UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $73.00

Goldman upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00 from $85.00 previously

Jefferies upgraded GE HealthCare from Hold to Buy and set a new price target of $103.00 from $95.00 previously

UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $74.00 from $84.00 previously

BTIG Research upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00

SD - GE HealthCare Technologies Inc. (0001932393) (Filer)

SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

10-Q - GE HealthCare Technologies Inc. (0001932393) (Filer)

8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

DEFA14A - GE HealthCare Technologies Inc. (0001932393) (Filer)

DEF 14A - GE HealthCare Technologies Inc. (0001932393) (Filer)

8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

Issued on behalf of Ventripoint Diagnostics Ltd.A Toronto-based small-cap is converting clinical validation into real-world hospital deployments at the moment AI cardiac imaging procurement is reorganizing globallyNEW YORK, May 19, 2026 /CNW/ -- USA News Group News Commentary — Cardiology has become one of the proving grounds for medical artificial intelligence, and the procurement environment around it has shifted hard in the last twelve months. Hospital networks are no longer content to evaluate clinical accuracy in isolation; they want department-level economic proof before they sign deployment contracts. That shift is reshaping which AI imaging companies can convert pilot data into recur

The company will showcase the latest iRT solution, MIM software innovations, and BK Medical technology – advancing speed, connectivity, and personalized medicine across the cancer care pathway. At the European Society for Radiotherapy and Oncology (ESTRO) 2026 Congress in Stockholm, GE HealthCare (NASDAQ:GEHC) will highlight a portfolio of AI-enabled solutions designed to support clinicians across radiation therapy, theranostics, and image-guided interventions. The company's presence underscores its focus on reducing workflow complexity, improving coordination across departments, and enabling more timely and personalized cancer care. According to the World Health Organization, cancer

GE HealthCare to showcase next-gen technologies including helium-free 1.5T MR, advanced 3T scanner and state-of-the-art AI-powered workflow at ISMRM 2026 Advanced MR research tools help simplify collaboration and speed development, empowering researchers to push boundaries As the global magnetic resonance (MR) community convenes for the International Society for Magnetic Resonance in Medicine (ISMRM) 2026 Annual Meeting, GE HealthCare (NASDAQ:GEHC) today announced advancements in research tools and MR systems that aim to accelerate discovery, strengthen collaboration across research programs, and turn innovation into meaningful clinical achievements. GE HealthCare continues to inve

Revenue growth of 7.4%, including Organic revenue growth* of 2.9% Total orders up 1.1% organically versus 10.3% growth in the year-ago period; book-to-bill of 1.07 times and backlog of $21.8 billion Profitability in the quarter was impacted by a discrete PDx supplier issue that has since been resolved Net income margin of 7.6% and Adjusted earnings before interest and taxes (EBIT) margin* of 13.5%; diluted earnings per share (EPS) of $0.85 and Adjusted EPS* of $0.99 Cash flow from operating activities of $290 million and Free cash flow* of $112 million For the full-year 2026, Company reaffirms topline growth driven by healthy global end market demand; reduces profit and Free

GE HealthCare (NASDAQ:GEHC) announced today a strategic evolution to its operations and executive leadership team to help shape the company's next chapter of growth and better serve patients and customers globally. The changes will also position the company to enhance execution, accelerate innovation, and create efficiencies. These changes are effective immediately. Phil Rackliffe has been appointed President and Chief Executive Officer of Advanced Imaging Solutions (AIS), a new segment that combines Imaging and Advanced Visualization Solutions (AVS) to create a $14.6 billion segment.1 This combination brings together GE HealthCare's two largest segments to create a more focused and conne

GE HealthCare (NASDAQ:GEHC) is announcing that members of its management team will present at the following upcoming investor conferences. Bank of America's 2026 Health Care Conference – Tuesday, May 12, 2026 at 10:40 am PT / 1:40 pm ET / 12:40 pm CT Jefferies Global Healthcare Conference – Wednesday June 3, 2026 at 9:20 am ET / 8:20 am CT Webcasts for each event can be accessed on the GE HealthCare website: https://investor.gehealthcare.com/news-events/events on the dates and times listed above. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and soft

Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agents A manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol's clinical development under FDA Fast Track designation The program demonstrates GE HealthCare's commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (NASDAQ:GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic

The expanded collaboration builds on the companies' existing joint initiative by bringing to market enhanced capabilities of DeepHealth's new AI-powered Breast Suite, including ProFound Pro and Safeguard Review GE HealthCare to feature latest technologies to help ensure optimized breast care outcomes across mammography and ultrasound at SBI's 2026 Breast Cancer Imaging Symposium GE HealthCare (NASDAQ:GEHC) today announced an expanded collaboration with DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), to further the innovation, commercialization, and adoption of advanced AI-powered mammography tools. The an

VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The American heart care market is undergoing a structural shift that most retail investors haven't noticed yet. The U.S. cardiovascular devices sector is on track to nearly double, from $22.08 billion in 2025 to $41.29 billion by 2032, fueled by aging demographics and a wave of next-generation diagnostic platforms[1]. At the same time, 75% of U.S. health systems are now rolling out AI-powered clinical tools, with cardiac imaging and documentation leading the charge[2]. That convergence of hardware growth and software integration is creating asymmetric upside for companies building the infra

bkActiv provides real-time visualization and now offers digital integration with the Stealth AXiS surgical navigation system, together bringing planning, navigation and robotics into a unified workflow Digital integration designed to help neurosurgeons assess anatomy in real-time and support surgical precision and clinical confidence Collaboration builds on existing strategic alliance between GE HealthCare and Medtronic to accelerate next-generation technology innovation across the enterprise GE HealthCare today announced a digital integration between the GE HealthCare bkActiv™ intraoperative ultrasound (iUS) system and the Medtronic Stealth AXiS™ surgical navigation system, which

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s

BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa

Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy

Revenue growth of 7.4%, including Organic revenue growth* of 2.9% Total orders up 1.1% organically versus 10.3% growth in the year-ago period; book-to-bill of 1.07 times and backlog of $21.8 billion Profitability in the quarter was impacted by a discrete PDx supplier issue that has since been resolved Net income margin of 7.6% and Adjusted earnings before interest and taxes (EBIT) margin* of 13.5%; diluted earnings per share (EPS) of $0.85 and Adjusted EPS* of $0.99 Cash flow from operating activities of $290 million and Free cash flow* of $112 million For the full-year 2026, Company reaffirms topline growth driven by healthy global end market demand; reduces profit and Free

GE HealthCare (NASDAQ:GEHC) will announce its first quarter 2026 financial results before the market opens on Wednesday, April 29, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutic

Expands GE HealthCare's enterprise imaging footprint by delivering comprehensive, end‑to‑end solutions across ambulatory, teleradiology, and hospital care settings Advances GE HealthCare's D3 strategy by accelerating the development of disease‑focused smart devices and solutions enabled by digital (cloud and software) and artificial intelligence (AI) capabilities Enhances a fully connected, cloud‑first imaging ecosystem with an expanded GE HealthCare portfolio of AI, digital tools, and SaaS offerings designed to improve clinical operations Tuck‑in acquisition expected to strengthen the Imaging portfolio, increase recurring revenue mix, and support sustainable top‑line growth and p

The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the first quarter of 2026 payable on May 15, 2026, to all shareholders of record as of April 3, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world's most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Imaging, Advanced Visualization Solutions, Patie

Company exceeds topline and earnings per share expectations; demonstrates operational resilience Fourth quarter 2025 highlights(1) Revenue growth of 7.1%, including Organic revenue growth* of 4.8%, driven primarily by the U.S. and Europe, the Middle East and Africa (EMEA) Net income margin of 10.3% and Adjusted earnings before interest and taxes (EBIT) margin* of 16.7% Diluted earnings per share (EPS) of $1.29 and Adjusted EPS* of $1.44 Cash flow from operating activities of $1.0 billion and Free cash flow* of $916 million Full year 2025 highlights(1) Revenue growth of 4.8%, including Organic revenue growth* of 3.5% Organic orders growth of 5.2% Net income margin o

GE HealthCare (NASDAQ:GEHC) will announce its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February 4, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innova

The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the fourth quarter of 2025 payable on February 13, 2026, to all shareholders of record as of January 9, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for mo

Revenue growth was 6% and Organic revenue growth* was 4% year-over year, driven by Europe, the Middle East and Africa (EMEA) and the U.S. Organic orders growth was 6% with growth across all segments Net income margin was 8.7%; Adjusted earnings before interest and taxes (EBIT) margin* was 14.8% Diluted earnings per share (EPS) were $0.98; Adjusted EPS* was $1.07 Cash flow from operating activities was $593 million; Free cash flow* was $483 million Excluding tariff impacts, margin and EPS would have exceeded prior year Raises the lower end of full-year 2025 Adjusted EPS* guidance range and reaffirms all other metrics GE HealthCare (NASDAQ:GEHC) today reported fina

GE HealthCare (NASDAQ:GEHC) will announce its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical te

The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the third quarter of 2025 payable on November 14, 2025 to all shareholders of record as of October 24, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)